- Home
- BCLI vs ACXP Comparison
BCLI vs ACXP Comparison
Compare BCLI & ACXP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BCLI
- ACXP
- Stock Information
- Founded
- BCLI 2000
- ACXP 2017
- Country
- BCLI United States
- ACXP United States
- Employees
- BCLI N/A
- ACXP N/A
- Industry
- BCLI Biotechnology: Biological Products (No Diagnostic Substances)
- ACXP Biotechnology: Pharmaceutical Preparations
- Sector
- BCLI Health Care
- ACXP Health Care
- Exchange
- BCLI Nasdaq
- ACXP Nasdaq
- Market Cap
- BCLI 9.9M
- ACXP 9.0M
- IPO Year
- BCLI N/A
- ACXP 2021
- Fundamental
- Price
- BCLI $1.21
- ACXP $0.36
- Analyst Decision
- BCLI Strong Buy
- ACXP Strong Buy
- Analyst Count
- BCLI 1
- ACXP 1
- Target Price
- BCLI $30.00
- ACXP $12.00
- AVG Volume (30 Days)
- BCLI 35.3K
- ACXP 235.2K
- Earning Date
- BCLI 03-31-2025
- ACXP 05-13-2025
- Dividend Yield
- BCLI N/A
- ACXP N/A
- EPS Growth
- BCLI N/A
- ACXP N/A
- EPS
- BCLI N/A
- ACXP N/A
- Revenue
- BCLI N/A
- ACXP N/A
- Revenue This Year
- BCLI $170.09
- ACXP N/A
- Revenue Next Year
- BCLI N/A
- ACXP N/A
- P/E Ratio
- BCLI N/A
- ACXP N/A
- Revenue Growth
- BCLI N/A
- ACXP N/A
- 52 Week Low
- BCLI $1.05
- ACXP $0.35
- 52 Week High
- BCLI $11.25
- ACXP $3.33
- Technical
- Relative Strength Index (RSI)
- BCLI 30.68
- ACXP 26.25
- Support Level
- BCLI $1.12
- ACXP $0.40
- Resistance Level
- BCLI $1.59
- ACXP $0.45
- Average True Range (ATR)
- BCLI 0.11
- ACXP 0.03
- MACD
- BCLI -0.02
- ACXP 0.00
- Stochastic Oscillator
- BCLI 17.31
- ACXP 6.21
About BCLI Brainstorm Cell Therapeutics Inc.
Brainstorm Cell Therapeutics Inc is a biotechnology company. The company is developing novel adult stem cell therapies for debilitating neurodegenerative disorders such as Amyotrophic Lateral Sclerosis (ALS, also known as Lou Gehrig's disease), Progressive Multiple Sclerosis (PMS), and Parkinson's disease (PD). Brainstorm's NurOwn, its proprietary process for the propagation of Mesenchymal Stem Cells (MSC) and differentiation into neurotrophic factor-(NTF) secreting cells (MSC-NTF), and their transplantation at, or near, the site of damage, offers the hope of more effectively treating neurodegenerative diseases.
About ACXP Acurx Pharmaceuticals Inc.
Acurx Pharmaceuticals Inc is a clinical stage biopharmaceutical company developing a new class of antibiotics for infections caused by bacteria listed as priority pathogens by the World Health Organization, Centers for Disease Control and Prevention and Food and Drug Administration.